Literature DB >> 29077214

Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage?

Shuichi Aoki1, Mark Cobbold2, Andrew X Zhu2, Dan G Duda1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29077214      PMCID： PMC5826834          DOI： 10.1002/hep.29617

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  10 in total

Review 1.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

Authors:  Scott Wilhelm; Christopher Carter; Mark Lynch; Timothy Lowinger; Jacques Dumas; Roger A Smith; Brian Schwartz; Ronit Simantov; Susan Kelley
Journal:  Nat Rev Drug Discov       Date:  2006-10       Impact factor: 84.694

Review 2.  Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy.

Authors:  Silvia von Karstedt; Antonella Montinaro; Henning Walczak
Journal:  Nat Rev Cancer       Date:  2017-05-24       Impact factor: 60.716

3.  CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.

Authors:  Yunching Chen; Rakesh R Ramjiawan; Thomas Reiberger; Mei R Ng; Tai Hato; Yuhui Huang; Hiroki Ochiai; Shuji Kitahara; Elizabeth C Unan; Tejaswini P Reddy; Christopher Fan; Peigen Huang; Nabeel Bardeesy; Andrew X Zhu; Rakesh K Jain; Dan G Duda
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

Review 4.  HCC and angiogenesis: possible targets and future directions.

Authors:  Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2011-03-08       Impact factor: 66.675

Review 5.  Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.

Authors:  Josep M Llovet; Virginia Hernandez-Gea
Journal:  Clin Cancer Res       Date:  2014-03-03       Impact factor: 12.531

6.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

Review 7.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

Authors:  Virginia Hernandez-Gea; Sara Toffanin; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-09       Impact factor: 22.682

8.  A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.

Authors:  T Ciuleanu; I Bazin; D Lungulescu; L Miron; I Bondarenko; A Deptala; M Rodriguez-Torres; B Giantonio; N L Fox; P Wissel; J Egger; M Ding; R N Kalyani; R Humphreys; M Gribbin; W Sun
Journal:  Ann Oncol       Date:  2016-01-22       Impact factor: 32.976

9.  A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice.

Authors:  Chun-Hung Liu; Guann-Jen Chern; Fu-Fei Hsu; Kuan-Wei Huang; Yun-Chieh Sung; Hsi-Chien Huang; Jiantai Timothy Qiu; Sheng-Kai Wang; Chu-Chi Lin; Chien-Hsun Wu; Han-Chung Wu; Jia-Yu Liu; Yunching Chen
Journal:  Hepatology       Date:  2018-01-29       Impact factor: 17.425

10.  Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.

Authors:  Yunching Chen; Yuhui Huang; Thomas Reiberger; Annique M Duyverman; Peigen Huang; Rekha Samuel; Lotte Hiddingh; Sylvie Roberge; Christina Koppel; Gregory Y Lauwers; Andrew X Zhu; Rakesh K Jain; Dan G Duda
Journal:  Hepatology       Date:  2014-02-18       Impact factor: 17.425
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.